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Introduction
Over the last years we have observed a renaissance of
intraoperative radiotherapy (IORT). IORT is based on
the delivery of a large single dose of electrons (IOEBRT)
or X-rays (IOXRT) through a surgical wound to irradiate
the tumor or the tumor bed. High dose rate afterloading
brachytherapy (IOHDR) can also be used as a form
of intraoperative treatment. IORT can be used in the
treatment of different cancer locations: head and neck,
breast, brain, stomach, pancreas, extrahepatic bile ducts,
colorectum, lung, bladder, cervix, uterus, vagina and soft
tissues [1-3]. A single dose of IORT is more effective
than an identical dose of conventional fractionated
external beam radiation therapy (EBRT). Tumor control
probability increases with the escalation of the radiation
dose. IORT allows to protect normal tissues, which may
be shielded or placed outside of the irradiated volume.
Initially, IORT was used as a sole treatment modality;
doses ranged from 25 Gy to 40 Gy [4]. More recently,
IORT has been used in combination with EBRT [5]. In
a majority of cases a 10-20 Gy boost dose was used.
Application of EBRT should be started 2-4 weeks after
surgery.
Description of the PRS400 Photon Radiosurgery
System
The PRS400 Photon Radiosurgery System (Carl Zeiss
Surgical GmbH) is a portable equipment designed for
intraoperative radiotherapy [6, 7]. The PRS400 has been
approved by the FDA for intraoperative treatment. This
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The aim of this study is to present a new method of intraoperative radiotherapy (IORT) using the PRS400 Photon Radiosurgery
System. IORT is a method of irradiation inside the tumor bed or tumor, aimed at dose escalation and local control probability
increase and sparing normal tissues. IORT can be used alone, or in combination with external beam radiation therapy. The
PRS400 Photon Radiosurgery System is a mobile miniature X-ray source dedicated for IORT. PRS400 generates soft X-ray with
a maximum emitted energy of 50 keV. The depth dose falls very rapidly with depth of the soft tissue (1/r3). PRS400 can be used
in different anatomical localisations. The advantage of PRS400 is that it can be used in any operating room, usually without
special shielding.
Nowa metoda Êródoperacyjnej radioterapii przy u˝yciu rentgenowskiego aparatu do radiochirurgii
Celem pracy jest przedstawienie nowej metody radioterapii Êródoperacyjnej (RÂ) przy wykorzystaniu urzàdzenia PRS400.
RÂ jest metodà leczenia pozwalajàcà na podwy˝szenie dawki w guzie lub w obszarze lo˝y po guzie, w celu zwi´kszenia
prawdopodobieƒstwa miejscowego wyleczenia nowotworu, przy równoczesnym oszcz´dzeniu zdrowych tkanek. Najistotniejszà
cz´Êcià PRS400 jest miniaturowe êród∏o promieniowania rentgenowskiego, wytwarzajàce mi´kkie promieniowanie X
o maksymalnej energii 50 keV. Spadek procentowej dawki g∏´bokoÊciowej jest bardzo szybki (1/r3). Zestaw PRS 400 mo˝e byç
zastosowany w leczeniu nowotworów w ró˝nych lokalizacjach anatomicznych. Zaletà PRS400 jest mo˝liwoÊç wykonania RÂ
w ka˝dej sali operacyjnej bez zastosowania specjalnych os∏on.
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system is also called the INTRABEAMTM System, and
can be used in any operating room, usually without special
shielding. There are no logistic and technical problems
with patient transportation from the operating room to
the radiotherapy department and back. This system can
be used to irradiate the tumor bed, as well as the tumor
itself. For intracranial applications the PRS400 is
combined with a stereotactic frame (the ACCUBEAMTM
System) [8, 9]. The PRS400 Photon Radiosurgery System
consists of the X-Ray Source (XRS) and the control
console (CC), (Figure 1). The XRS is placed in a special
mobile arm, keeping the applicator stable in the desired
position during the IORT. XRS is small (17.5 cm x 11 cm
x 7 cm) and it weighs only 1.62 kg. The XRS is equipped
with a 10 cm long probe (3.2 mm diameter). This probe is
enclosed in a spherical applicator, which is placed in the
tumor bed. The XRS is connected to a control console
with a low voltage cable (max. 15V) and plugged into 2-
phase 220 V power. There is no risk of an electrical
hazard to the patient and the surgeon. The CC is used to
set up treatment parameters and control the XRS during
operation.
Three values of high voltage are generated within
the XRS: 30, 40 or 50 kV. The currently used intensities
are 5, 10, 20 or 40 µA. X-rays are generated by an
electron beam which strikes the tip of the probe. For
50 kV voltage the maximum emitted X-ray energy is
50 keV, but the effective energy is approx. 20 keV. The
dose rate is related to the diameter of the applicator and
the distance to the applicator and ranges from
0.28 Gy/minute for 5 cm to 13 Gy/minute for 1 cm. The
radiation surface is near to spheric. In soft tissue the
delivered dose decreases very rapidly (1/r3), due to the low
energy of the X-ray. In the distance of three meters from
the radiation source, the dose rate is lower than
20 µGy/min.
Before each IORT verification tests of the system,
calibration procedures and treatment time calculations
are performed by medical physicists. The verification
procedures are relatively time-consuming (about 2-3
hours). For this reason the PRS400 system is usually
prepared on the day before the application. The manu-
facturing company recommends periodical calibration of
the XRS to quantify the depth-dose rate characteristics.
The XRS is not sterile, during surgery it is covered with
a sterile transparent plastic bag. The applicators are
sterilized before each treatment session.
The procedure of IORT
IORT is an interdisciplinary procedure, which requires
good cooperation of the members of the treatment team,
i.e. radiation oncologists, surgeons, anstesiologists, nurses,
radiation therapists and physicists. After surgical re-
section, the radiation oncologist and the surgeon deter-
mine the volume for irradiation. The choice of the
applicator size depends on the tumor or the tumor bed.
The diameters of spherical applicators range from 1.5 to
5.0 cm with an 0.5 cm step (Figure 2). The sterile
applicator is inserted into the tumor bed (Figure 3). The
normal tissues are shielded, if necessary. Shields can
attenuate radiation approximately ten times (equivalent of
0.05 mm Pb screen for energy of 50 keV). The control
console is located outside the operating room. The
radiation therapist selects energy, dose rate and delivered
dose. At any time, the operator of the CC may interrupt
the IORT. The treatment time depends on the applicators
size and the selected dose. The whole procedure of IORT
is completed in approximately 20 to 40 minutes. During
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Figure 1. The PRS400 Photon Radiosurgery System consists 
of the X-Ray source and the control console
Figure 2. The set of spherical applicators
Figure 3. The applicator immobilization inside the tumor bed
radiotherapy, the anesthesia monitoring system is located
outside of the operating room, thus allowing to supervise
the patient. A movable shield is placed in the entrance to
the operating room, allowing the anstesiologist to observe
the patient directly.
Discussion
Local tumor control (LTC) is the most important issue in
oncological treatment. The probability of TLC increases
with higher doses. The planned dose often cannot be
delivered by external radiotherapy beacause of normal
tissue reactions. IORT is one of the methods of dose
escalation. Thus, the therapeutic gain of the IORT is
achieved by the dose increase within the tumor or within
tumor bed and spares normal tissues. In this type of
radiotherapy, the radiation injury of normal tissues could
be minimized by shifting from the irradiated field,
shielding or excluding normal tissue by using appropriate
electron beam energy.
The most common sequeles of IORT are peripheral
nerve, bile duct and ureter injuries. In patients with locally
advanced colorectal cancer the probability of causing
neuropathy increases with doses exceeding 15 Gy [10].
The obstruction of ureters and bile ducts can cause renal
and liver disfunction. The pancreatic duct is particulary
sensitive. Vascular injury can be observed with doses
exceeding 30 Gy [11]. Other complications have seldom
been reported. The ratio of postoperative complications
remained the same, irrespectively of whether IORT or
surgery only was applied.
Direct visualisation of the tumor during surgery
allows for greater accuracy in determing treatment
volume. IORT limits the likelihood of missing surgical
margins, the risk of geographical error and marginal
recurrence. This method of radiotherapy minimizes the
risk of sad misses, thus being contrary to brachytherapy
[12].
In many cancer locations, IORT is used as a sole
adjuvant treatment modality. In the treatment of gastric
cancer IORT is performed directly after tumor resection
and before oesophagoenterostomy. Abe irradiated the
tumor bed and the regional lymph nodes using a single
dose, which ranged from 18 Gy to 40 Gy [1, 2]. Nodal
metastases were controlled by a single dose higher than 30
Gy. IORT was also used in paliative treatment of
inoperabile tumors.
It appears, that a combination of IORT and EBRT
may allow for better local tumor control and should
improve the results of treatment. The tumor or the tumor
bed with regional lymph nodes are irradiated from
fractionated EBRT. The IORT boost is delivered to
regions at a high risk of reccurence. Application of IORT
can shorten the treatment time by, approximately, 1-2
weeks. In the radical treatment of abdominal malignan-
cies sole EBRT is insufficient. Unlike in IORT, dose
escalation from external beam radiotherapy can cause
dangerous radiation injury. EBRT can be used both as
preoperative and postoperative treatment. Radiotherapy
should be conventionally fractionated up to the total dose
of 45-50 Gy. Preoperative EBRT would allow to decrease
the tumor volume and should facilitate the operation.
Consequently, the volume of boost is decreased.
The application of IORT using the PRS400 system
has been investigated. The number of published clinical
studies is too limited to recognize IOXRT as standard
treatment [6, 7]. Intraoperative electron-beam radiation
therapy (IOEBRT), intraoperative high dose rate brachy-
therapy (IOHDR) and intraoperative X-rays radiation
therapy (IOXRT) are all different techniques of intraope-
rative radiotherapy. From the radiobiological point of
view, it is not possible to transfer IOEBRT or IOHDR
experiences directly to IOXRT. IOEBRT allows for
a more homogeneous dose distribution within target than
X-rays. The accelerators can produce electron beams of
different energies from 6 MeV to 25 MeV. The surface
dose (Ds) of electron beams ranges from 75% for 6 MeV
to almost 100% for 18 MeV [13]. Ds is proportional to
energy of electrons. For lower electron beam energy build
up dose region may play have clinical impact. The dose
delivery to CTV may be approximately 20% lower, than
the calculated dose. Reni observed the influence of
electron beam energy on local control [14]. Local control
of pancreatic cancer was l7% for 6 MeV compared to
37% for higher beam energies. It is clinically significant
that the perecntage of the depth dose depends on the
field size. There is a more rapid dose fall-down for smaller
fields. The advantage of electron beams is the big dose
gradient which allows to protect critical organs. Usually
80% or 90% isodoses are used for delivered dose
calculations. For IOHDR the dose inhomogeneity is
smaller than for IOXRT. IOXRT and IOHDR achieve
the maximum dose on the surface of applicator. The
percentage depth dose from IOXRT is related to
applicator size, which results in greater heterogenity of
dose within the target volume and decreases faster for
smaller applicators. This dose distribution is advantageous
for normal tissues, but not for the target volume. We
recomend a standard depth to a dose calculation of 5 mm
or 10 mm. It is necessary to report a contact dose.
A limitation of IORT is the accessibility of the site
limited by the shape of the applicator. IOEBRT some-
times may be difficult to use in selected site, e.g. the head
and neck, the brain, the anterior abdominal wall, the
subdiaphragmatic areas, the anterior and lateral pelvic
walls, due to the size and build of the applicators. At The
Ohio State University, IOHDR was used in such cases
[15]. The PRS400 can be easily used for such locations
because the diameter of the smallest applicator is 1.5 cm.
However, the disadvantage of PRS400 is the fact that
only spherical applicators are used. 
Conclusions
The main advantage of IORT is the very accurate
localisation of the target volume. It allows to escalate the
dose to the tumor or the tumor bed, and thus the
probablility of the locoregional control may increase.
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Surrounding normal tissues are spared and radiation
injuries are rare.
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